18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
23:43 , Jan 14, 2019 |  BC Extra  |  Politics & Policy

House begins campaign to publicize and politicize drug pricing

Requests for pricing and cost information sent Monday by the House Oversight and Reform Committee to a dozen biopharma companies mark the start of what is certain to be a sustained campaign by House Democrats...
20:30 , Nov 30, 2018 |  BC Week In Review  |  Company News

Pfizer extends Lyrica exclusivity by six months in U.S.

Pfizer Inc. (NYSE:PFE) said FDA granted pediatric exclusivity to its blockbuster neurology drug Lyrica pregabalin, extending the product's patent protection by six months to June 30, 2019. Lyrica is approved in the U.S. to treat...
16:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Nov. 14 decision that invalidated second medical use patent...
23:32 , Nov 14, 2018 |  BC Extra  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
17:42 , Aug 3, 2018 |  BC Week In Review  |  Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said on Pfizer's 2Q18 earnings call. Read said the current rebate structure is not...
22:59 , Jul 31, 2018 |  BC Extra  |  Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said Tuesday on Pfizer's 2Q18 earnings call. Read said the current rebate structure is...
18:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

For Pfizer's units, three is the magic number

Pfizer Inc. (NYSE:PFE) will reorganize into three distinct business units: Innovative Health, Established Medicines and Consumer Healthcare. The pharma's current structure includes two distinct business units: Pfizer Innovative Health and Pfizer Essential Health. Under the...